Answers are grounded in this paper and cite their sources.
Lymphadenopathy and lymphadenitis are common clinical findings but represent different biological processes and markedly different risks across age groups and healthcare settings. Enlarged lymph nodes may reflect a self-limiting immune response, focal infection, systemic inflammatory disease or neoplastic involvement; lymphadenitis denotes inflammation of nodal tissue and may be suppurative, granulomatous or non-infectious. Confusion between the finding and its cause can produce both diagnostic delay and unnecessary investigation. This critical narrative review evaluates published evidence on prevalence, aetiology, pathophysiology, diagnostic assessment, disease-specific staging, medical management and evolving surgical approaches. Peer-reviewed research, clinical guidance and pivotal randomised trials were considered through 16 August 2026, with methodological scrutiny directed at referral bias, diagnostic reference standards, treatment-selection effects and transferability across populations. The synthesis finds that the apparent prevalence of malignancy changes substantially with clinical setting, while node size or imaging appearance alone cannot safely determine aetiology. For suspected infection, microbiological confirmation and targeted antimicrobial treatment are preferable to indiscriminate empirical therapy; particular considerations apply to tuberculosis, non-tuberculous mycobacteria and paediatric suppurative disease. Fine-needle aspiration offers a relatively low-morbidity initial sampling route in appropriately selected adults, whereas core or excisional biopsy remains necessary when tissue architecture or molecular classification is decisive. Staging is meaningful only after identification of the underlying condition: lymphoma, head and neck carcinoma, breast cancer and melanoma employ distinct systems that cannot be applied to undifferentiated lymphadenopathy. Contemporary oncological trials support reduced nodal surgery for carefully defined patient groups, although surveillance infrastructure and accompanying systemic or radiotherapy treatments limit generalisation. Important evidence gaps remain in representative prevalence estimation, equitable access to timely diagnosis, prospective comparison of biopsy pathways and functional outcomes after surgery. Clinically useful decisions depend on integrated risk assessment, diagnostic stewardship and disease-specific multidisciplinary care rather than a single universal lymph-node algorithm.
No takes yet. Share an insight, caveat, or question.
Ndeh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: